NRG Therapeutics gains further funding from Parkinson’s UK
Investment will be used to support the development of disease modifying drugs to treat Parkinson’s disease
Read More
Tag: NRG Therapeutics
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
